Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Liabilities from Discontinued Operations: 2023

  • Seres Therapeutics' Liabilities from Discontinued Operations was N/A to $109.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was $109.4 million, marking a year-over-year change of. This contributed to the annual value of $109.4 million for FY2023, which is N/A change from last year.
  • According to the latest figures from Q4 2023, Seres Therapeutics' Liabilities from Discontinued Operations is $109.4 million.
  • Over the past 5 years, Seres Therapeutics' Liabilities from Discontinued Operations peaked at $109.4 million during Q4 2023, and registered a low of $109.4 million during Q4 2023.
  • For the 1-year period, Seres Therapeutics' Liabilities from Discontinued Operations averaged around $109.4 million, with its median value being $109.4 million (2023).